Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are now recruiting volunteers for Oxford Vaccine Group's new Ebola study: Evaluating Optimal Vaccine Schedules against Ebola (EVOLVE)

RECRUITING NOW!

You are invited to take part in a study investigating new vaccines against Ebola virus disease (EVD). The current outbreak of EVD in West Africa is estimated by the World Health Organization to have caused more than 10,000 deaths to date and is still ongoing. There is no specific treatment or cure for Ebola and an effective vaccine would be an important step in controlling the spread of disease. The study is being run by the Oxford Vaccine Group, part of the University of Oxford. 

►       If you are aged 18 to 65 years old and in good health you may be eligible to take part in the study

►       We will provide reimbursement for your time, inconvenience and travel

Interested individuals may attend a screening visit at our site to discuss this further and for their suitability for the study to be assessed.  If you would like to find out more, you can contact us via:

Ebolavaccine.org.uk

01865 857420

info@ovg.ox.ac.uk


This study is being run by the Oxford Vaccine Group, part of the University of Oxford and is funded by Crucell Holland BV.

Similar stories

Alternating vaccines trial expands to include two additional vaccines

COVID-19 Clinical Trials Vaccinology

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

COVID-19 Vaccinology

Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

COVID-19 Vaccinology

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

COVID-19 Vaccinology

- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall - Vaccine 100% effective against severe or critical symptomatic COVID-19 - No safety concerns reported

Professor Matthew Snape named NIHR Senior Investigator

Awards & Appointments Vaccinology

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

COVID-19 Research Vaccinology

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.